Cardiovascular Theranostics, Istituto Cardiocentro Ticino, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Department of Medical Sciences, University of Torino, Italy.
Nephrol Dial Transplant. 2023 Feb 28;38(3):764-777. doi: 10.1093/ndt/gfac259.
A long-standing effort is dedicated towards the identification of biomarkers allowing the prediction of graft outcome after kidney transplant. Extracellular vesicles (EVs) circulating in body fluids represent an attractive candidate, as their cargo mirrors the originating cell and its pathophysiological status. The aim of the study was to investigate EV surface antigens as potential predictors of renal outcome after kidney transplant.
We characterized 37 surface antigens by flow cytometry, in serum and urine EVs from 58 patients who were evaluated before, and at 10-14 days, 3 months and 1 year after transplant, for a total of 426 analyzed samples. The outcome was defined according to estimated glomerular filtration rate (eGFR) at 1 year.
Endothelial cells and platelets markers (CD31, CD41b, CD42a and CD62P) in serum EVs were higher at baseline in patients with persistent kidney dysfunction at 1 year, and progressively decreased after kidney transplant. Conversely, mesenchymal progenitor cell marker (CD1c, CD105, CD133, SSEEA-4) in urine EVs progressively increased after transplant in patients displaying renal recovery at follow-up. These markers correlated with eGFR, creatinine and proteinuria, associated with patient outcome at univariate analysis and were able to predict patient outcome at receiver operating characteristics curves analysis. A specific EV molecular signature obtained by supervised learning correctly classified patients according to 1-year renal outcome.
An EV-based signature, reflecting the cardiovascular profile of the recipient, and the repairing/regenerative features of the graft, could be introduced as a non-invasive tool for a tailored management of follow-up of patients undergoing kidney transplant.
长期以来,人们一直致力于寻找能够预测肾移植后移植物结局的生物标志物。循环体液中的细胞外囊泡(EVs)是一种很有吸引力的候选物,因为其携带的货物反映了来源细胞及其病理生理状态。本研究旨在探讨 EV 表面抗原作为肾移植后肾脏结局的潜在预测因子。
我们通过流式细胞术对 58 例患者的血清和尿液 EVs 中的 37 种表面抗原进行了特征分析,这些患者在移植前、移植后 10-14 天、3 个月和 1 年共进行了 426 次分析。根据 1 年时的估算肾小球滤过率(eGFR)定义结局。
基线时血清 EV 中内皮细胞和血小板标志物(CD31、CD41b、CD42a 和 CD62P)在 1 年时肾功能持续障碍的患者中较高,并在肾移植后逐渐下降。相反,在随访中肾功能恢复的患者中,尿液 EV 中间充质祖细胞标志物(CD1c、CD105、CD133、SSEEA-4)在移植后逐渐增加。这些标志物与 eGFR、肌酐和蛋白尿相关,在单变量分析中与患者结局相关,并能在接受者操作特征曲线分析中预测患者结局。通过有监督学习获得的特定 EV 分子特征能够根据 1 年的肾脏结局正确分类患者。
一种基于 EV 的特征,可以反映受者的心血管特征,以及移植物的修复/再生特征,可作为一种非侵入性工具,用于对接受肾移植的患者进行随访的个体化管理。